yingweiwo

Vitamin D3-d3

Cat No.:V42528 Purity: ≥98%
Vitamin D3-d3 is the deuterium labelled form of Vitamin D3.
Vitamin D3-d3
Vitamin D3-d3 Chemical Structure CAS No.: 80666-48-4
Product category: New3
This product is for research use only, not for human use. We do not sell to patients.
Size Price
500mg
1g
Other Sizes

Other Forms of Vitamin D3-d3:

  • 1α,25-Dihydroxyvitamin D3-(23,24,25,26,27-13C5) solution
  • Alfacalcidol-d7 (1-hydroxycholecalciferol-d7; 1.alpha.-Hydroxyvitamin D3-d7)
  • Calcitriol-13C3 (1,25-Dihydroxyvitamin D3-13C3)
  • Vitamin D3-13C3 (vitamin D3 13C3)
  • Vitamin D3-13C5 (vitamin D3-13C5; Cholecalciferol-13C5; Colecalciferol-13C5)
  • Cholecalciferol (Vitamin D3)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description
Vitamin D3-d3 is the deuterium labelled form of Vitamin D3. Vitamin D3 (Cholecalciferol; Colecalciferol) is a naturally occurring form of vitamin D that can induce cell differentiation and cancer/tumor cell growth/proliferation after metabolic activation.
Biological Activity I Assay Protocols (From Reference)
ln Vitro
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Cholecalciferol is readily absorbed from the small intestine if fat absorption is normal. Moreover, bile is necessary for absorption as well. In particular, recent studies have determined aspects about the absorption of vitamin D, like the fact that a) the 25-hydroxyvitamin D metabolite of cholecalciferol is absorbed to a greater extent than the nonhydroxy form of cholecalciferol, b) the quantity of fat with which cholecalciferol is ingested does not appear to largely affect its bioavailability, and c) age does not apparently effect vitamin D cholecalciferol.
It has been observed that administered cholecalciferol and its metabolites are excreted primarily in the bile and feces.
Studies have determined that the mean central volume of distribution of administered cholecalciferol supplementation in a group of 49 kidney transplant patients was approximately 237 L.
Studies have determined that the mean clearance value of administered cholecalciferol supplementation in a group of 49 kidney transplant patients was approximately 2.5 L/day.
Readily absorbed from small intestine (proximal or distal); cholecalciferol may be absorbed more rapidly and completely than ergocalciferol.
Elimination: Biliary/renal. /Vitamin D and analogs/
Many vitamin D analogs are readily absorbed from the GI tract following oral administration if fat absorption is normal. The presence of bile is required for absorption of ergocalciferol and the extent of GI absorption may be decreased in patients with hepatic, biliary, or GI disease (e.g., Crohn's disease, Whipple's disease, sprue). Because vitamin D is fat soluble, it is incorporated into chylomicrons and absorbed via the lymphatic system; approximately 80% of ingested vitamin D appears to be absorbed systemically through this mechanism, principally in the small intestine. Although some evidence suggested that intestinal absorption of vitamin D may be decreased in geriatric adults, other evidence did not show clinically important age-related alterations in GI absorption of the vitamin in therapeutic doses. It currently is not known whether aging alters the GI absorption of physiologic amounts of vitamin D. /Vitamin D analogs/
After absorption, ergocalciferol and cholecalciferol enter the blood via chylomicrons of lymph and then associate mainly with a specific alpha-globulin (vitamin D-binding protein). The hydroxylated metabolites of ergocalciferol and cholecalciferol also circulate associated with the same alpha-globulin. 25-Hydroxylated ergocalciferol and cholecalciferol are stored in fat and muscles for prolonged periods. Once vitamin D enters systemic circulation from lymph via the thoracic duct or from skin, it accumulates in the liver within a few hours.
For more Absorption, Distribution and Excretion (Complete) data for CHOLECALCIFEROL (7 total), please visit the HSDB record page.
Metabolism / Metabolites
Within the liver, cholecalciferol is hydroxylated to calcifediol (25-hydroxycholecalciferol) by the enzyme vitamin D-25-hydroxylase. At the kidney, calcifediol subsequently serves as a substrate for 1-alpha-hydroxylase, yielding calcitriol (1,25-dihydroxycholecalciferol), the biologically active form of vitamin D3.
Metabolic activation of cholecalciferol and ergocalciferol occurs in 2 steps, the first in the liver and the second in the kidneys. Metabolic activation of calcifediol occurs in the kidneys; dihydrotachysterol, alfacalcidol and doxercalciferol are activated in the liver.
Normal combined (ie, 25-hydroxyvitamin D) plasma concentrations of 25-hydroxycholecalciferol (calcifediol) and 25-hydroxyergocalciferol, which are the major circulating metabolites of cholecalciferol and ergocalciferol, have been reported to range from 8-80 ng/mL, depending on the assay used, and vary with exposure to UV light. A commonly reported range for the lower limit of normal is 8-15 ng/mL, depending on geographic location (eg, Southern California would be higher than Massachusetts).
In the liver, ergocalciferol and cholecalciferol are converted in the mitochondria to their 25-hydroxy derivatives by the enzyme vitamin D 25-hydroxylase. Vitamin D 25-hydroxylase activity is regulated in the liver by concentrations of vitamin D and its metabolites; therefore, increases in the systemic circulation of the 25-hydroxy metabolites following exposure to sunlight or ingestion of vitamin D are relatively modest compared with cumulative production or intake of the vitamin. Serum concentrations of nonhydroxylated vitamin D are short-lived as a result of storage in fat or metabolism in the liver. In the kidneys, these metabolites are further hydroxylated at the 1 position by the enzyme vitamin D 1-hydroxylase to their active forms, 1,25-dihydroxycholecalciferol (calcitriol) and 1,25-dihydroxyergocalciferol. ... Activity of the vitamin D 1-hydroxylase enzyme requires molecular oxygen, magnesium ion, and malate and is regulated principally by PTH in response to serum concentrations of calcium and phosphate, and perhaps by circulating concentrations of 1,25-dihydroxyergocalciferol and 1,25-dihydroxycholecalciferol. Other hormones (ie, cortisol, estrogens, prolactin, and growth hormone) also may influence the metabolism of cholecalciferol and ergocalciferol.
The hepatic enzyme system responsible for 25-hydroxylation of vitamin D /(vitamin D-25 hydroxylase)/ is associated with the microsomal and mitochondrial fractions of homogenates and requires NADPH (nicotinamide adenine dinucleotide phosphate, reduced form) and molecular oxygen. ... The enzyme system /in kidney/ responsible for 1-hydroxylation of 25-OHD (25-hydroxycholecalciferol) /(25-OHD-1-alpha-hydroxylase)/ is associated with mitochondria in the proximal tubules. It is a mixed function oxidase and requires molecular oxygen and NADPH as cofactors. Cytochrome P450, a flavoprotein, and ferredoxin are components of the enzyme complex.
Biological Half-Life
At this time, there have been resources that document the half-life of cholecalciferol as being about 50 days while other sources have noted that the half-life of calcitriol (1,25-dihydroxyvitamin D3) is approximately 15 hours while that of calcidiol (25-hydroxyvitamin D3) is about 15 days. Moreover, it appears that the half-lives of any particular administration of vitamin d can vary due to variations in vitamin d binding protein concentrations and genotype in particular individuals.
The Vitamin /D/ disappears from plasma with a half-life of 19 to 25 hr but is stored in fat depots for prolonged periods. ... The 25-hydroxy derivative has a biological half-life of 19 days ... The plasma half-life of calcitriol /(1,25-dihydroxy-vitamin D)/ is estimated to be between 3 and 5 days in human beings ...
Toxicity/Toxicokinetics
Protein Binding
The protein binding documented for cholecalciferol is 50 to 80%. Specifically, in the plasma, vitamin D3 (from either diet or the skin) is bound to vitamin D-binding protein (DBP) produced in the liver, for transport to the liver. Ultimately, the form of vitamin D3 reaching the liver is 25-hydroxylated, and such 25-hydroxycholecalciferol is bound to DBP (α2-globulin) whilst circulating in the plasma.
Toxicity Data
LC50 (rat) = 130-380 ppm/4hr
Interactions
Corticosteroids counteract the effects of vitamin D analogs. /Vitamin D analogs/
Concurrent administration of thiazide diuretics and pharmacologic doses of vitamin D analogs in patients with hypoparathyroidism may result in hypercalcemia which may be transient and self-limited or may require discontinuance of vitamin D analogs. Thiazide-induced hypercalcemia in hypoparathyroid patients is probably caused by increased release of calcium from bone. /Vitamin D analogs/
Excessive use of mineral oil may interfere with intestinal absorption of vitamin D analogs. /Vitamin D analogs/
Orlistat may result in decreased GI absorption of fat-soluble vitamins such as vitamin D analogs. At least 2 hours should elapse between (before or after) any orlistat dose and vitamin D analog administration ... . /Vitamin D analogs/
For more Interactions (Complete) data for CHOLECALCIFEROL (6 total), please visit the HSDB record page.
References

[1]. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

[2]. Role of local bioactivation of vitamin D by CYP27A1 and CYP2R1 in the control of cell growth in normal endometrium and endometrial carcinoma. Lab Invest. 2014 Jun;94(6):608-22.

Additional Infomation
Therapeutic Uses
Bone Density Conservation Agents; Vitamins
MEDICATION (VET): Nutritional factor (Antirachitic)
Therapeutic doses of specific vitamin D analogs are used in the treatment of chronic hypocalcemia, hypophosphatemia, rickets, and osteodystrophy associated with various medical conditions including chronic renal failure, familial hypophosphatemia, and hypoparathyroidism (postsurgical or idiopathic, or pseudohypoparathyroidism). Some analogs have been found to reduct elevated parathyroid hormone concentrations in patients with renal osteodystrophy associated with hyperparathyroidism. Theoretically, any of the vitamin D analogs may be used for the above conditions, However, because of their pharmacologic properties, some may be more useful in certain situations than others. Alfacalcidol, calcitriol, and dihydrotachysterol are usually preferred in patients with renal failure since these patients have impaired ability to synthesize calcitriol from cholecalciferol and ergocalciferol; therefore, the response is more predictable. In addition, their shorter half-lives may make toxicity easier to manage (hypercalcemia reverses more quickly). Ergocalciferol may not be the preferred agent in the treatment of familial hypophosphatemia or hypoparathyroidism because the large doses needed are associated with a risk of overdose and hypercalcemia; dihydrotachysterol and calcitriol may be preferred. /Included in US product labeling/
Drug Warnings
Studies have shown that the elderly may have an increased need for vitamin D due to a possible decrease in the capacity of the skin to produce previtamin D3 or a decrease in exposure to the sun or impaired renal function or impaired vitamin D absorption.
Doses of vitamin D analogs that do not exceed the physiologic requirement are usually nontoxic. However, some infants and patients with sarcoidosis or hypoparathyroidism may have increased sensitivity to vitamin D analogs. /Vitamin D analogs/
Acute or chronic administration of excessive doses of vitamin D analogs or enhanced responsiveness to physiologic amounts of ergocalciferol or cholecalciferol may lead to hypervitaminosis D manifested by hypercalcemia. /Vitamin D analogs/
Decreased renal function without hypercalcemia has also been reported in patients with hypoparathyroidism after long-term vitamin D analog therapy. Before therapy with vitamin D analogs is initiated, serum phosphate concentrations must be controlled. To avoid ectopic calcification, the serum calcium (in mg/dL) times phosphorus (in mg/dL) should not be allowed to exceed 70. Because administration of vitamin D analogs may increase phosphate absorption, patients with renal failure may require adjustment in the dosage of aluminum-containing antacids used to decrease phosphate absorption. /Vitamin D analogs/
For more Drug Warnings (Complete) data for CHOLECALCIFEROL (10 total), please visit the HSDB record page.
Pharmacodynamics
The in vivo synthesis of the predominant two biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of vitamin D3 cholecalciferol (or D2) occurs in the liver to yield 25-hydroxyvitamin D while the second hydroxylation happens in the kidneys to give 1, 25-dihydroxyvitamin D. These vitamin D metabolites subsequently facilitate the active absorption of calcium and phosphorus in the small intestine, serving to increase serum calcium and phosphate levels sufficiently to allow bone mineralization. Conversely, these vitamin D metabolites also assist in mobilizing calcium and phosphate from bone and likely increase the reabsorption of calcium and perhaps also of phosphate via the renal tubules. There exists a period of 10 to 24 hours between the administration of cholecalciferol and the initiation of its action in the body due to the necessity of synthesis of the active vitamin D metabolites in the liver and kidneys. It is parathyroid hormone that is responsible for the regulation of such metabolism at the level of the kidneys.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C27H44O
Molecular Weight
387.656153678894
Exact Mass
387.358
CAS #
80666-48-4
Related CAS #
Vitamin D3;67-97-0
PubChem CID
117064495
Appearance
White to off-white solid powder
LogP
7.619
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
1
Rotatable Bond Count
6
Heavy Atom Count
28
Complexity
610
Defined Atom Stereocenter Count
5
SMILES
[2H]C(=C\1CC[C@@H](C/C1=C(\[2H])/C=C/2\CCC[C@]3([C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C)O)[2H]
InChi Key
QYSXJUFSXHHAJI-GLSUUORTSA-N
InChi Code
InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1/i3D2,13D
Chemical Name
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]-1-deuterioethylidene]-4-(dideuteriomethylidene)cyclohexan-1-ol
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.5796 mL 12.8979 mL 25.7958 mL
5 mM 0.5159 mL 2.5796 mL 5.1592 mL
10 mM 0.2580 mL 1.2898 mL 2.5796 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency
CTID: NCT02553447
Phase: N/A    Status: Active, not recruiting
Date: 2024-10-08
Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy
CTID: NCT05259527
Phase: Phase 2    Status: Suspended
Date: 2024-09-03
Pilot Study- Treat to Target Vitamin D in End Stage Renal Disease
CTID: NCT04167111
Phase: N/A    Status: Withdrawn
Date: 2024-09-03
Rapid Normalization of Vitamin D Deficiency in PICU
CTID: NCT03742505
Phase: Phase 3    Status: Recruiting
Date: 2024-09-03
Vitamin D in Dialysis Patients - Diagnostic and Therapeutic Management
CTID: NCT06571344
Phase:    Status: Recruiting
Date: 2024-08-26
View More

Oral Vitamin D Supplementation Prevent Peritoneal Dialysis-related Peritonitis
CTID: NCT05860270
Phase: Phase 4    Status: Recruiting
Date: 2024-08-06


Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients
CTID: NCT03406897
Phase: Phase 1/Phase 2    Status: Completed
Date: 2024-07-24
Effects Of Vitamin D On Bone, Muscle, And Adipose Tissue In Obese Subjects
CTID: NCT06508242
Phase: Phase 4    Status: Recruiting
Date: 2024-07-18
Vitamine D in Drug Resistant Epilepsy
CTID: NCT03475225
Phase: Phase 3    Status: Completed
Date: 2024-07-12
30000 IU Per Week Vitamin D Treatment in PCOS Patients
CTID: NCT04840238
Phase: Phase 2    Status: Completed
Date: 2024-06-24
Controlled, Randomized, Four-arm Comparative, Open Label, Multi-centric Clinical Trial to Compare the Efficacy and Safety Parameters of the Once-a-week or Once-a-month Administered 7000 IU, or 30000 IU Vitamin D (Cholecalciferol) to a 1000 IU Dosage Applied Daily in Vitamin D Deficient Patients
CTID: NCT02069990
Phase: Phase 3    Status: Completed
Date: 2024-06-24
Ultra-high Dose Vitamin D for HSCT
CTID: NCT03759262
Phase: Phase 1    Status: Completed
Date: 2024-05-20
The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients
CTID: NCT03188796
Phase: Phase 3    Status: Recruiting
Date: 2024-05-17
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
CTID: NCT01787409
Phase: N/A    Status: Recruiting
Date: 2024-05-07
Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia
CTID: NCT05386784
Phase: Phase 4    Status: Completed
Date: 2024-04-17
Prevention of Postoperative Hypocalcemia of Oral Vitamin D Supplementation Before Total Thyroidectomy
CTID: NCT05216419
Phase: Phase 4    Status: Recruiting
Date: 2024-04-17
Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
CTID: NCT02100423
Phase: Phase 2    Status: Completed
Date: 2024-04-12
Association of Cathelicidin and Vitamin D Levels With the Category and Course of COPD
CTID: NCT05431218
Phase: Phase 4    Status: Completed
Date: 2024-04-12
Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients
CTID: NCT05045066
PhaseEarly Phase 1    Status: Recruiting
Date: 2024-04-09
Effect of Vitamin D Injection on Hypertrophic Scars and Keloids
CTID: NCT06301178
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-03-21
Vitamin D Supplementation in Individuals With a Chronic Spinal Cord Injury
CTID: NCT04652544
Phase: Phase 3    Status: Completed
Date: 2024-03-08
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
CTID: NCT04094688
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-02-26
The Role of Vitamin D in Neuroinflammatory on Drug Resistant Epilepsy
CTID: NCT06053281
PhaseEarly Phase 1    Status: Recruiting
Date: 2024-02-14
Vitamin D Supplementation in RNA-seq Profiles of Single-core Prostate Samples, Among Veterans
CTID: NCT04621500
Phase: Phase 2    Status: Completed
Date: 2024-01-31
High Oral Loading Dose of Cholecalciferol in Non-Alcoholic Fatty Liver Disease
CTID: NCT05578404
Phase: Phase 2    Status: Completed
Date: 2023-11-29
The Effect of Vitamin D3 Therapy on Vitamin D Status in Pregnant Women With Vitamin D Deficient and Insufficient
CTID: NCT06054919
Phase: Phase 2/Phase 3    Status: Active, not recruiting
Date: 2023-09-26
Serum 25-hydroxy Vitamin D [25(OH)D] Levels, Supplemental Vitamin D, and Parathyroid Hormone Levels in Premature Infants
CTID: NCT01469650
Phase: N/A    Status: Completed
Date: 2023-09-06
Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery
CTID: NCT00470353
Phase: N/A    Status: Terminated
Date: 2023-08-04
Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study
CTID: NCT04793529
Phase: N/A    Status: Completed
Date: 2023-07-27
Cholecalciferol Supplementation in Hemodialysis Patients
CTID: NCT05922696
Phase: Phase 2/Phase 3    Status: Completed
Date: 2023-06-28
The Effect of Supplementation of Vitamin D3 on Inflammation Induced by 100 km Running, Iron Metabolism and Erythropoiesis
CTID: NCT05880030
Phase: N/A    Status: Completed
Date: 2023-05-30
Effect of Preoperative High-dose Cholecalciferol in Prevention of Post-thyroidectomy Hypocalcaemia
CTID: NCT05586529
Phase: N/A    Status: Recruiting
Date: 2023-03-29
PRAgmatic Trial in Atopic Dermatitis Testing Long-term Control Effectiveness of New Phototherapy Regimen During Winter Coupled With Oral Vitamin D Supplementation vs. Placebo
CTID: NCT02537509
Phase: Phase 2    Status: Completed
Date: 2023-03-23
Mothers' Own Milk Optimization for Preterm Infants Project (MoMO PIP) Pilot Study
CTID: NCT04629534
Phase: Phase 4    Status: Terminated
Date: 2023-03-15
The Efficacy and Safety of Topical Vitamin D and Supplementation In Acne Vulgaris The Study of VDR, IL-1β, IL-6, IL-10 and IL-17 Expression
CTID: NCT05758259
Phase: Phase 4    Status: Enrolling by invitation
Date: 2023-03-07
Effect of Vitamin D and Denosumab on Bone Remodelling in Women With Postmenopausal Osteoporosis
CTID: NCT05372224
Phase: N/A    Status: Completed
Date: 2023-02-17
Vitamin D, Oxidative Stress and Inflammation in Hemodialysis
CTID: NCT05460338
Phase: Phase 2/Phase 3    Status: Completed
Date: 2023-02-06
The Effect of Cholecalciferol in Pre-frail Elderly
CTID: NCT04847947
Phase: Phase 3    Status: Completed
Date: 2023-01-26
Vitamin D Supplementation in Kidney Disease
CTID: NCT01229878
Phase: N/A    Status: Completed
Date: 2023-01-05
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
CTID: NCT03588884
Phase: Phase 4    Status: Completed
Date: 2022-12-09
Effectiveness of Inactive Vitamin D Supplementation in Non-Alcoholic Fatty Liver Disease Patients
CTID: NCT05613192
Phase: Phase 3    Status: Unknown status
Date: 2022-11-14
Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren
CTID: NCT02880982
Phase: Phase 3    Status: Completed
Date: 2022-09-08
D-vitamin And Graves' Disease; Morbidity And Relapse Reduction
CTID: NCT02384668
Phase: N/A    Status: Completed
Date: 2022-09-01
A Trial of Vitamin D Therapy in Patients With Heart Failure
CTID: NCT01125436
Phase: N/A    Status: Completed
Date: 2022-08-10
Vitamin D and Painful Diabetic Neuropathy
CTID: NCT05080530
Phase: N/A    Status: Unknown status
Date: 2022-07-21
Vitamin D supplementation to palliative cancer patients - A double blind, randomised controlled trial
CTID: null
Phase: Phase 2    Status: Completed
Date: 2017-05-15
Effect of High-Dose Vitamin D3 on 28-Day Mortality in Adult Critically Ill Patients with Severe Vitamin D Deficiency
CTID: null
Phase: Phase 3    Status: Ongoing, GB - no longer in EU/EEA
Date: 2017-01-03
Vitamin D in secondary prevention of benign paroxysmal positional vertigo: a prospective, multicenter, randomized, placebo-controlled, double-blind study (VitD@BPPV)
CTID: null
Phase: Phase 2, Phase 3    Status: Completed
Date: 2016-11-29
A phase IV, randomised, parallel study to compare a monthly administration of vitamin D3 (D-CURE®) to a daily administration of vitamin D3 (VISTA-D3®).
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-10-28
PROVENT: A randomised, double blind, placebo controlled feasibility study to examine the clinical effectiveness of aspirin and/or Vitamin D3 to prevent disease progression in men on active surveillance for prostate cancer
CTID: null
Phase: Phase 3    Status: Completed
Date: 2014-12-29
A phase IV, randomised, cross-over study to estimate the influence of food on the 25-hydroxyvitamin D3 serum level after vitamin D3 (D-CURE®) supplementation.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2014-10-13
’D-STAPH’
CTID: null
Phase: Phase 2    Status: Completed
Date: 2014-05-06
Supplémentation en vitamine D chez des enfants et adolescents suivis en néphrologie pédiatrique: étude de l’efficacité du protocole habituel de service (cholécalciférol) et de son impact sur la calciurie.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2014-02-25
vitamin D and nonspecific musculoskeletal pain in non-Wesren immigrants
CTID: null
Phase: Phase 3, Phase 4    Status: Ongoing
Date: 2013-12-24
Can Vitamin D supplementation improve Hepatitis C cure rates: A pilot multicentre randomised controlled clinical trial
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-11-07
DOuleurs chroniques et VItamine D : une étude pilote en médecine de ville.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2013-09-11
Effects of high and low dose vitamin D on postprandial leukocyte activation, oxidative stress and vascular function in healthy overweight and obese females
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2013-09-09
Mucosal immune regulation by high dose vitamin D treatment in Crohn’s disease
CTID: null
Phase: Phase 3    Status: Completed
Date: 2013-08-01
Vitamin D And Lifestyle Intervention for Gestational Diabetes Mellitus (GDM) Prevention - A European multicentre, randomised trial: Vitamin D limb.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2013-07-05
Controlled, randomized, four-arm comparative, open label, multi-centric trial to compare the efficacy and safety parameters of the once-a-week or once-a-month administered 7000 IU, or 30000 IU vitamin D (cholecalciferol) to a 1000 IU dosage applied daily in vitamin D deficient patients
CTID: null
Phase: Phase 3    Status: Completed
Date: 2013-02-19
A phase IV, randomised, double-blinded, parallel study to estimate the dose-response of vitamin D (D-CURE®) supplementation on the 25-hydroxyvitamin D serum concentration in patients with vitamin D deficiency.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2012-12-03
BEST-D (Biochemical efficacy and safety trial of vitamin D): a dose-finding trial assessing biochemical and vascular effects of high dose vitamin D
CTID: null
Phase: Phase 3    Status: Completed
Date: 2012-06-28
Feasibility study including a double blind (C)controlled study and an open label (C) controlled study for a larger randomised trial measuring the effect of oral vitamin D (I) on morbidity and mortality (O) in men and women aged 65-84 (P)
CTID: null
Phase: Phase 2    Status: Completed
Date: 2012-03-02
DALI dosing study of Vitamin D in obese pregnant women
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2011-08-03
The effects of oral vitamin D supplementation on cardiovascular disease risk in patients with Myalgic Encephalomyelitis /Chronic Fatigue Syndrome.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2011-02-15
Vitamin D supplementation and male infertility: a randomized double blinded clinical trial
CTID: null
Phase: Phase 4    Status: Completed
Date: 2011-02-10
The pharmacogenetics of vitamin D response in tuberculosis
CTID: null
Phase: Phase 3    Status: Completed
Date: 2011-01-20
Pilot study: Leucocyte actIvation and endothelial function after oral fat loading combined with VITamin D
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2011-01-12
VItamin D treatment Effect on retinal nerve fiber loss after Optic neuritis
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2010-07-01
Correction of vitamin D deficiency in critically ill patients: a randomized, doulbe-blind, placebo-controlled trial
CTID: null
Phase: Phase 3    Status: Completed
Date: 2010-05-03
Satunnaistettu, sokkoutettu, lumekontrolloitu tutkimus D-vitamiinin suurannoshoidosta
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-02-04
A randomized, double blind, placebo controlled, phase II, multi-centre pilot study to investigate the effects of vitamin D2 or D3 supplementation on metabolic parameters in people at risk of type 2 diabetes.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2009-12-22
A randomized placebo controlled trial of vitamin D3 supplementation to a vulnerable patientsgroup susceptible to uppertract respiratory infections.
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2009-12-16

CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2009-07-17
Vitamin D og kronisk nyreinsufficiens
CTID: null
Phase: Phase 3    Status: Completed
Date: 2009-06-15
The Effects of Oral Vitamin D Supplementation on Cardiovascular Disease Risk in UK South Asian Women
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2008-12-08
Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension?
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-11-18
Betydning af D-vitamin substitution hos overvægtige personer med lavt plasma D-vitamin niveau. Effekter på inflammatoriske markører samt fedt- og muskelmetabolisme.
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2008-11-03
Vitamin D and type 2 diabetes.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2008-09-30
DOES VITAMIN D REDUCE BLOOD PRESSURE AND LV MASS IN RESISTANT HYPERTENSIVE PATIENTS WITH VITAMIN D INSUFFICIENCY?
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-08-28
Impact of 25-hydroxy vitamin D deficiency and its correction on mineral and bone disorde among hemodialysis patients
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2008-06-03
Vitamin D therapy to reduce cardiovascular risk in Type 2 diabetes – the next steps
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-01-23
A Double-Blind Randomised Placebo-Controlled Trial of Vitamin D Supplements for Pregnant Women with Low Levels of Vitamin D in Early Pregnancy
CTID: null
Phase: Phase 3    Status: GB - no longer in EU/EEA
Date: 2007-12-03
Einfluss einer Vitamin D-Substitution auf die Insulinresistenz, die Stoffwechseleinstellung und die Lymphozytenfunktion bei Patienten mit Typ 2 Diabetes mellitus
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2007-06-13
A randomized, double-blind, parallel-group study evaluating efficacy and safety of MEGA tablets compared to Kalcipos® tablets in adult Subjects
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-10-25

Contact Us